Solesence, Inc. (SLSN) is a Romeoville, Illinois-based science and manufacturing company — formerly Nanophase Technologies — that formulates and produces mineral-based sun care, skin care and color cosmetics for brand partners, and supplies surface-engineered zinc oxide and titanium dioxide ingredients. The micro-cap, valued at roughly $105 million, has spent most of 2026 below $1.00 before a violent post-earnings re-rating.
In Wednesday's session the stock is trading near $1.48, a decline of $0.16, or 9.76%, from the previous completed close of $1.64 on Nov. 18. The direction is unambiguously negative, and the pullback follows a rally in which shares climbed from $0.91 on Nov. 12 to an intraday peak of $1.97 on Nov. 16. No verified news catalyst was found for the drop; the most defensible explanation is that buyers who captured the post-earnings jump are taking profits.
No company press release, SEC filing, or sell-side action dated to this session explains the decline. The relevant fundamental disclosure — the third-quarter report — was published before the market opened on Nov. 13 and has already been absorbed: revenue of $20.2 million, up 38% year over year, gross margin of 39.3%, up 1,550 basis points, and record net income of $3.7 million against a $1.0 million loss a year earlier.
The decline is therefore best characterized as technical in nature. The stock had gained roughly 67% in a single session on Nov. 13 and added another 11% across the following two sessions before stalling on Nov. 18. A retracement of that magnitude, on a name that routinely swings by 4% or more in a normal day, is consistent with speculative momentum unwinding rather than a reassessment of the business. Trading was also very thin relative to the earnings-day volume, which amplifies percentage moves in a stock with a small float.
The quarter did not erase several issues investors have flagged all year. Management reiterated that full-year 2026 EBITDA margins will land slightly below its previously communicated double-digit target because of a soft first half, and it did not raise full-year guidance despite the strong third quarter. Nine-month revenue of $48.5 million remained about 2.3% below the prior-year pace, meaning a record full year depends on fourth-quarter growth.
The company only recently completed a restatement of prior financial statements tied to inventory accounting and has disclosed material weaknesses in internal controls that it is still testing. Cash stood at $1.27 million at quarter-end, leaving little buffer against planned capital spending. Customer concentration remains high, with a handful of brand partners driving most revenue, and the stock has traded close to the Nasdaq minimum bid price for much of the year — a deficiency the current price level now appears to resolve.
Turnover in today's session was a fraction of the 10.0 million shares that traded on Nov. 13, when the earnings report triggered a volume explosion. Average daily volume over the past 90 sessions sits closer to 300,000 shares, so the post-earnings sessions were an outlier by a wide margin; the return to lighter volume is itself a signal that the initial buyer base has thinned.
The move was idiosyncratic rather than sector-driven. No broad consumer-staples, beauty, or small-cap benchmark decline of comparable size was evident, and there was no macro data release or policy headline tied to the timing. Technically, the stock has surrendered the $1.50 area and sits roughly 25% below the Nov. 16 intraday high of $1.97, though it remains well above its 50-day moving average near $1.00 — a level that marked the pre-earnings ceiling.
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news paired with an extreme, rare move. SLSN earns 17 out of 100.
The verified news component is weak for this session: nothing new was disclosed, and the only fundamental input was the already-public third-quarter report and the unchanged caution on full-year EBITDA margins. The price component is only moderately unusual. Today's 9.76% decline is roughly 2.5 times the stock's average absolute daily move of about 3.9% over the last 60 sessions, and moves of equal or greater size occurred just twice in that window — the 67% earnings surge and a 22% jump in October. A large but not unprecedented pullback following a genuine fundamental catalyst combines into a low overall score.
Attention now shifts to the fourth quarter, which management must deliver to secure a third consecutive year of record revenue against its target of at least $65 million in shipped and on-hand orders. The company typically reports full-year results in late March, and investors will focus on whether the 39.3% gross margin is a durable baseline or a favorable mix anomaly. Also relevant: progress on internal-control testing after the restatement, any commentary on new brand launches or pricing, and whether the broader FDA sunscreen-ingredient landscape creates formulation demand. Management has signaled it will begin attending investor conferences in 2027, which could improve visibility. Key risks include customer concentration, a cash cushion of barely $1 million, potential dilution if financing is needed, and the stock's tendency toward double-digit swings that cut both ways.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only the top performers earn a place in this featured section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. For traders navigating volatile micro-caps like this one, reviewing the trending lineup is a practical starting point — visit the page to see which robots are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SLSN's Aroon Indicator triggered a bullish signal on October 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 127 similar instances where the Aroon Indicator showed a similar pattern. In 99 of the 127 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 78%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on SLSN as a result. In 66 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for SLSN just turned positive on November 04, 2026. Looking at past instances where SLSN's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
SLSN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SLSN crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +11.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLSN advanced for three days, in 153 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for SLSN moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 52 cases where SLSN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLSN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SLSN broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.604) is normal, around the industry mean (21.731). P/E Ratio (-21.430) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (1.139) is also within normal values, averaging (1.902).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLSN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HouseholdPersonalCare